Clinical Trial: Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07774299) titled 'Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL' on Aug. 17.

Brief Summary: This trial is a prospective, multi-center, single-arm clinical research. The intention is to evaluate the efficacy and safety of pirtobrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL patients.

Study Start Date: Aug. 25

Study Type: INTERVENTIONAL

Condition: DLBCL

Intervention: DRUG: pirtobrutinib combined with BEAM

pirtobrutinib 200mg oral qd D-8-D-2; camustine: 300mg/m2 vgtt qd D-8; etoposide: 100mg/m2/d vgtt q12h D-7-D-4; cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 70mg...